Health CarePharmaceuticals & Biotechnology
  • Price (USD)0.4028
  • Today's Change-0.0059 / -1.44%
  • Shares traded500.00
  • 1 Year change-76.02%
  • Beta0.8754
Data delayed at least 15 minutes, as of Oct 21 2016 21:00 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Oct 21, 2016, the consensus forecast amongst 3 polled investment analysts covering CTI BioPharma Corp advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 10, 2016. The previous consensus forecast advised that CTI BioPharma Corp would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.

Research reports

S&P Capital IQ Quantitative Report

CTI BioPharma
12 pages, 22 Oct 2016

Ford Investor Services, Inc.

More ▼

Share price forecast

The 3 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 0.75, with a high estimate of 5.00 and a low estimate of 0.00. The median estimate represents a 86.20% increase from the last price of 0.4028.

Earnings history & estimates

On Aug 04, 2016, CTI BioPharma Corp reported 2nd quarter 2016 losses of -0.070 per share. This result exceeded the -0.10 consensus loss of the 2 analysts covering the company and under-performed last year's 2nd quarter results by 63.16%.
The next earnings announcement is expected on Nov 03, 2016.
Average growth rate+16.52%
CTI BioPharma Corp reported annual 2015 losses of -0.65 per share on Feb 16, 2016.
Average growth rate+19.02%
More ▼

Revenue history & estimates

CTI BioPharma Corp. had 2nd quarter 2016 revenues of 7.36m. This bettered the 905.00k estimate of the one analyst covering the company. This was 569.18% above the prior year's 2nd quarter results.
Average growth rate+301.15%
CTI BioPharma Corp. had revenues for the full year 2015 of 16.12m. This was 73.17% below the prior year's results.
Average growth rate+807.69%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.